# RiverHead Capital

> RiverHead Capital is a VC fund in Chaoyang backing Health Care and Medical. See 43 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chaoyang, China
- Total investments: 43
- Last investment: Jul 2026
- Lead investor: 35%
- Last fund: Jan 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/%E9%98%B3%E5%85%89%E8%9E%8D%E6%B1%87%E8%B5%84%E6%9C%AC%E6%8A%95%E8%B5%84%E7%AE%A1%E7%90%86%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/
- Website: http://www.riverheadcapital.cn/html/home/home.html

RiverHead Capital is a VC fund in Chaoyang focused on Health Care and Medical. River Head Capital is the private equity arm of the Sunshine Insurance Group.River Head Capital was established in January 2015. It is the first batch of insurance private fund pilot units approved by the China Insurance Regulatory Commission. The fund management scale has reached 17 billion yuan.Adhering to the corporate vision of “making lifebetter”, with the mission of “creating value, trustworthiness, investing resources in the most valuable companies, and gaining the trust of investors with excellent returns”, the company will actively deploy medical health and emerging Industries, emerging consumption, industrial mergers and acquisitions, real estate and other fields, through entrepreneurial support, strategic investment, financial investment, mergers and acquisitions, corporate restructuring, cross-border investment and other diversified ways to invest in enterprises, comprehensively enhance corporate value and support the healthy and sustainable development of enterprises. At present, River Head Capital has invested in a number of companies in the fields of medical, pharmaceutical, Internet, and innovative financial services.

## Contacts

5 contacts available for RiverHead Capital. Shizune tracks 2 team members at RiverHead Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/river-head-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $1.4M–$74M |
| Series B | $14M–$283M |
| Series C | $15M–$89M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 18 | 42% |
| Medical | 14 | 33% |
| Biotechnology | 13 | 30% |
| Biopharma | 5 | 12% |
| Semiconductor | 5 | 12% |

51 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 26% |
| Series B | 10 | 23% |
| Series C | 5 | 12% |
| Venture - Series Unknown | 4 | 9% |
| Angel | 3 | 7% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 36 | 84% |
| United States | 1 | 2% |
| Cayman Islands | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Shenghao Shi | Managing Partner | 6 | https://shizune.co/investors/profile/shenghao-shi |
| Wenwen Zhang | CEO | 0 | https://shizune.co/investors/profile/wenwen-zhang-5d41 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Linghang Huaxin | Linghang Huaxin is a semiconductor technology company. It focuses on the research and development of high-reliability memory chips and modules. |  | Series A | Jul 30, 2026 |  |
| Delova Biotech | Delova Biotech specializes in the field of pain treatment. It uses the company's rich R&D experience and special preparation technology platform to improve existing drugs and conduct research and development of improved new analgesics in China and the United States. | $88.6M | Series C | Jul 22, 2026 |  |
| Lingtai Krypton Biotechnology | Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. |  | Series A | Jun 26, 2026 |  |
| Startorus Fusion | Startorus Fusion focuses on developing and commercializing fusion energy technologies, aiming for controllable device miniaturization, commercialization, and fast iteration, integrating design, R&D, operation, and maintenance. | $73.5M | Series A | May 07, 2026 |  |
| Layerwave Bio | Layerwave Bio is a developer of IVD diagnostic instrument reagents and biomedical scientific research instruments. |  | Venture - Series Unknown | Apr 27, 2026 |  |
| Ningkang Ruizhu | Ningkang Ruizhu is a targeted drugs developer. | $14.1M | Series A | Dec 05, 2025 |  |
| Cascade | Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation. | $42.4M | Series B | Nov 28, 2025 |  |
| Perception Origin | Perception Origin is a leading domestic supplier of commercial spaceborne payloads, specializing in the development and advancement of Synthetic Aperture Radar (SAR) technology. |  | Series A | Nov 11, 2025 |  |
| Brosmed | Brosmed is a provider of interventional vascular therapy services. |  | Venture - Series Unknown | Jun 19, 2025 |  |
| Hisky Medical | Hisky focuses on non-invasive disease diagnosis technologies and develops FibroTouch. | $13.8M | Series D | Mar 24, 2025 |  |

10 of 43 investments shown.

## Co-investors
- [CICC](https://shizune.co/investors/profile/cicc) — VC Fund, 4 deals together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 4 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 3 deals together
- [Longpan Investment](https://shizune.co/investors/profile/longpan-investment) — VC Fund, 3 deals together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 2 deals together
- [Broad Vision Funds](https://shizune.co/investors/profile/broad-vision-funds) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Wintermute Ventures](https://shizune.co/investors/profile/wintermute-ventures) — VC Fund
- [Wintermute](https://shizune.co/investors/profile/wintermute-trading) — VC Fund
- [1confirmation](https://shizune.co/investors/profile/1confirmation) — VC Fund

## Featured in investor lists
- [Fitness Investors in China](https://shizune.co/investors/fitness-investors-china)
- [Fitness VC Funds in China](https://shizune.co/investors/fitness-vc-funds-china)
- [All Investors in Cayman Islands](https://shizune.co/investors/investors-cayman-islands)
- [All VC Funds in Cayman Islands](https://shizune.co/investors/vc-funds-cayman-islands)
- [Biotechnology VC Funds in LATAM](https://shizune.co/investors/biotechnology-vc-funds-latam)
- [Biotech VC Funds in LATAM](https://shizune.co/investors/biotech-vc-funds-latam)

## FAQ

### What does RiverHead Capital invest in?

RiverHead Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 43 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is RiverHead Capital's check size?

RiverHead Capital typically joins rounds of $1.4M–$74M at Series A, $14M–$283M at Series B and $15M–$89M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RiverHead Capital participates in.

### How do I contact RiverHead Capital?

Public channels for RiverHead Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at RiverHead Capital?

The team at RiverHead Capital includes Shenghao Shi (Managing Partner) and Wenwen Zhang (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co